Abstract
INTRODUCTION
Mild acute pancreatitis (MAP), the mild form of acute pancreatitis, accounts for 80% of AP, and is mainly caused by gallstones and alcohol abuse [1] . Once inflammation damages the pancreas, the inactive digestive enzymes, such as trypsinogen, are activated, leading to autodigestion of the pancreas and triggering AP [2] . Immunocompetent cells, including monocytes and macrophages, participate in the development and progression of AP [3] [4] [5] . However, how monocytes regulate the pathogenesis of AP has not been clarified.
Monocytes are circulating white blood cells (WBCs), which differentiate into macrophages when they enter the tissue [6] . Macrophages can be classically activated as M1 or alternatively activated as M2 cells [7] . The M1 macrophages can produce many types of pro-inflammatory cytokines, including interleukin (IL)-12, IL-1β and IL-6, and defense against infectious pathogens and tumors. The M2 macrophages are characterized by expressing anti-inflammatory cytokines (e.g., IL-10) and many other factors that regulate immune responses and tissue repair, but may promote tumor growth and metastasis [7, 8] . Different types of macrophage responses and their relative IL-10 and IL-12 have been associated with different types of inflammatory diseases and are valuable for evaluating disease severity [9, 10] . The M1 and M2 classification is initially proposed for macrophages, and can be extended to human peripheral blood monocytes [11] . The expression of both M1 and M2 markers is detected in circulating peripheral blood mononuclear cells (PBMCs), and the different types of polarized monocytes in peripheral blood are associated with different diseases [11] [12] [13] . However, little is known on whether the numbers of peripheral blood different types of polarized monocytes and the levels of plasma IL-10 and IL-12 can be valuable for evaluating the severity of MAP.
Peripheral blood monocytes and macrophages express CD14, which is one of the pattern-recognition receptors and a co-receptor of toll-like receptor [14, 15] . MAC387 antibody can recognize calprotectin, a complex of intracellular myeloid-related proteins (MRPs) 8 and MRP14. The blood-derived MAC387+ monocytes/ macrophages are recently infiltrating monocytes/ macrophages and are important inflammatory components [16] [17] [18] . CD163 is a hemoglobin scavenger receptor expressed by peripheral blood monocytes and macrophages, polarizes monocytes/macrophages toward M2-phenotype and is crucial for the resolution of inflammation [19, 20] . CD115 is macrophage colonystimulating factor receptor (CSF-1R) and engagement of CSF-1R by CSF-1 polarizes toward M2-type macrophages and enhances their function [21] . CD115 is expressed by human monocytes. How different subsets of M1 and M2 monocytes regulate the pathogenesis of MAP has not been explored. Notably, anti-CD115 can inhibit inflammatory osteolysis and has potential antitumor effect, suggesting that CD115+ M2 monocytes/ macrophages are associated with inflammation and tumor growth [21] [22] [23] . However, there is no report on the numbers of CD115+ monocytes in MAP patients.
In this study, we characterized the numbers of different subsets of monocytes and the levels of plasma IL-10 and IL-12 in patients with newly diagnosed MAP and health controls. Furthermore, we analyzed the potential association of the numbers of different subsets of monocytes and the levels of plasma IL-10 and IL-12 with the levels of plasma C-reactive protein (CRP) and the acute physiology and chronic health evaluation (APACHE) II scores in MAP patients.
MATERIALS AND METHODS

Patients and controls
A total of 24 patients with new-onset MAP were recruited at the inpatient service of the Department of Gastroenterology, the Second Part of the First Hospital of Jilin University (Changchun, China) from July 2015 to March 2016. All patients met the Atlanta criteria of MAP [24] . Another 13 sex-, age-and ethnicitymatched healthy subjects were recruited from the Physical Examination Center of our hospital during the same period, and served as the controls. These controls had no history of autoimmune diseases, chronic inflammatory diseases, or allergies. The disease severity of individual patients was evaluated by APACHE II score. Patients were excluded if she/ he had a history of malignant tumor, autoimmune diseases, any of other chronic inflammatory diseases, or had received immunosuppressive drugs within the past 3 mo. Written informed consent was obtained from individual subjects. The experimental protocol was established according to the guidelines of the Declaration of Helsinki and was approved by the Human Ethics Committee of Jilin University. The demographic and clinical characteristics of individual participants are shown in Table 1 .
Clinical data
The clinical data of each subject were collected from the hospital records. These data included age, sex, height, body weight, body mass index (BMI) and laboratory tests. Individual subjects were subjected to routine laboratory tests for full blood cell counts, the concentrations of plasma CRP, amylase (AMY) and lipase activities. The levels of plasma CRP were determined by scatter turbidimetry using a Siemens special protein analyzer (Siemens Healthcare Diagnostics Products, GmbH, Munich, Germany). The concentrations of plasma AMY and lipase were determined by ADVIA 1650 biochemical analyzer (Bayer, Pittsburg, PA, United States).
Flow cytometry analysis
Heparinized fasting venous blood samples (6 millilitres, mL) were collected from the median cubital vein of individual MAP patients (within 72 h after upper abdominal pain occurred) and control subjects, and PBMCs were isolated by density-gradient centrifugation using Ficoll-Paque Plus (Amersham Biosciences, Little Chalfont, United Kingdom). PBMCs at 1 × 10 6 /tube were stained in duplicate with BV510-anti-CD14, PE-anti-CD115 (BD Biosciences, Franklin Lakes, NJ, United States), PE/Cy7-anti-CD163 and APC/Cy7-anti-206 (Biolegend, San Diego, CA, United States) in the dark at 4 ℃ for 30 min. After being washed, the cells were fixed and permeabilized using a fixation/ permeabilization kit (BD Biosciences), followed by intracellular staining with FITC-anti-MAC387 (Abcam, Cambridge, United Kingdom). The fluorescence-and isotype-matched antibodies served as negative controls.
To detect the function, PBMCs (10 6 cells/well)
were stimulated in duplicate with 50 ng/mL of lipopolysaccharide, phorbol myristate acetate and 1.0 µg/mL of ionomycin (Sigma-Aldrich, St. Louis, United States) in 10% fetal bovine serum RPMI 1640 (complete medium) for 2 h at 37 ℃ in 5% CO2 and exposed to Brefeldin A (GolgiPlug; BD Biosciences) for 4 h, as described previously in a study from our laboratory [15, 25] . After being washed, the cells were stained with BV510-anti-CD14 and PE/Cy7-anti-CD163, fixed and permeabilized using the permeabilization solution, followed by intracellular staining with BV421-anti-IL-12 and PE-CF594-anti-IL-10 (BD Biosciences). The real positive and negative cells were distinguished by fluorescence minus one (FMO) and the cells were stained with all of the fluorochromes, except for the one that was being measured. 
Increased numbers of MAC387+ M1 monocytes in the MAP patients
The blood-derived MAC387+ monocytes/macrophages are recently infiltrating monocytes/macrophages and CD14+CD163-MAC387+ monocytes/macrophages are important inflammatory components [16] [17] [18] . To further understand the importance of monocytes, the numbers of peripheral blood CD14+CD163-MAC387+ and CD14+CD163+MAC387+ cells in the MAP patients and controls were characterized by flow cytometry ( Figure 2 ). The numbers of CD14+CD163-MAC387+ cells in the MAP patients were significantly higher than that in the controls (P = 0.0091). However, there was no statistically significant difference in the numbers of CD14+CD163+MAC387+ cells between the MAP patients and controls (P = 0.9619). Thus, increased numbers of MAC387+ M1 monocytes were present in the MAP patients.
Increased numbers of CD115+ M2 monocytes in the MAP patients
Although there was no statistically significant difference in the numbers of CD14+CD163+ M2 monocytes between the MAP patients and controls, there are different subsets of M2 monocytes with different surface markers and varying functions [15, 26] . M2 monocytes can express CD206 (the mannose receptor) and/or CD115 [15, 27] . To understand the importance of different subsets of M2 monocytes, the numbers of peripheral blood CD206+ and/or CD115+ M2 monocytes in the MAP patients and controls were further analyzed by flow cytometry. As shown in Figure 3 , the numbers of CD14+CD163+CD115+ and CD14+CD163+CD115+CD206+ monocytes in the MAP patients were significantly higher than those in the controls (P = 0.0072 and P < 0.0001, respectively). However, there was no statistically significant difference in the numbers of CD14+CD163+CD206+ monocytes between the MAP patients and controls (P = 0.9873). Together, increased numbers of CD115+ M2 monocytes were present in the MAP patients.
Increased cytokine production in the MAP patients
M1 monocytes can produce IL-12 and are critical for inflammation. In contrast, M2 monocytes produce IL-10, which controls inflammation and promotes tumor growth. To understand the functions of M1 and M2 monocytes in the pathogenic process of MAP, the numbers of peripheral blood IL-12+ M1 monocytes and IL-10+ M2 monocytes were characterized by flow cytometry. There was no significant difference in the fluorescent intensity of anti-IL-12 and anti-IL-10 signals in monocytes between the MAP patients and controls (data not shown). As shown in Figure 4 , the numbers of IL-12+ M1 monocytes were significantly higher in the MAP patients than the controls (P = 0.0202). Conversely, the numbers of IL-10+ M2 monocytes were Ashland, OR, United States). Finally, the numbers of different subsets of monocytes were calculated, based on the numbers of monocytes in individual subjects and expressed as the numbers of cells per mL.
Cytometric bead array analysis of plasma cytokines
The concentrations of plasma IL-10 and IL-12 were determined by Cytometric bead array (CBA), according to the manufacturer's protocol (BD Biosciences) with minor modification. Briefly, plasma samples (50 µL) from individual subjects were subjected in duplicate to analysis of the levels of plasma IL-10 and IL-12 using the CBA kit on a FACSAria II (Beckton, Dickinson and Company). The concentrations of plasma cytokines were quantified using the CellQuestPro and CBA software (Becton, Dickinson and Company). The limitation of detection for IL-10 and IL-12 is 3.3 pg/mL and 1.9 pg/mL, respectively.
Statistical analysis
Data are expressed as median and range. The difference between two groups was analyzed by the Mann-Whitney U nonparametric test. The relationship between variables was evaluated using the Spearman rank correlation test. All the statistical analyses were performed by the SPSS version 19.0 software. A twosided P value of < 0.05 was considered statistically significant.
RESULTS
Increased numbers of M1 monocytes in MAP patients
To understand the importance of monocytes, 24 MAP patients and 13 controls were recruited. Among all the patients, 7 cases were induced by alcohol, 11 cases by hypertriglyceridemia, and 6 by cholelithiasis, and the length of hospital stay was 7-10 d. There was no significant difference in the distribution of age, sex and BMI as well as the number of PBMCs between the MAP patients and controls ( Table 1 ). The numbers of peripheral blood WBCs and neutrophils were significantly higher in the patients than those in the controls (P < 0.05; Table 1 ). The values of AMY, lipase and CRP were significantly higher in the MAP patients than that in the controls. In addition, MAP patients displayed variable values of APACHE II score.
The numbers of peripheral blood CD14+CD163-M1 and CD14+CD163+ M2 monocytes in the MAP patients and controls were characterized by flow cytometry. As shown in Figure 1 , the numbers of CD14+CD163-M1 monocytes were significantly higher in the patients than that in the controls (P = 0.0049). In contrast, there was no significant difference in the numbers of CD14+CD163+ M2 monocytes between the MAP patients and controls (P = 0.8362). Collectively, increased numbers of CD14+CD163-M1 monocytes existed in MAP patients. significantly lower in the MAP patients than the controls (P = 0.022). As a result, the ratios of the numbers of CD14+CD163-IL-12+ to CD14+CD163+IL-10+ monocytes in the MAP patients were significantly higher than that in the controls. Further CBA analysis indicated that the concentrations of plasma IL-12 and IL-10 were significantly higher in the MAP patients than that in the controls (P = 0.0065 and P = 0.0001, respectively). Hence, increased levels of plasma pro-inflammatory IL-12 and anti-inflammatory IL-10 existed in the MAP patients.
Correlation analysis of clinical parameters with different subsets of monocytes and cytokines in the MAP patients
Finally, the potential relationship between the values of clinical parameters and the numbers of different subsets of monocytes and the levels of cytokines was analyzed in the MAP patients. As shown in Figure 5 , the levels of plasma CRP were positively correlated with the numbers of CD14+CD163-(R = 0.5009, P = 0.0127) and CD14+CD163-MAC387+ (R = 0.5079, P = 0.0113) M1 monocytes, and CD14+CD163+CD115+ (R = 0.4565, P = 0.0249) M2 monocytes, but not with CD14+CD163+ M2 monocytes in this population. Furthermore, the APACHE II scores were positively correlated with the numbers of CD14+CD163+CD115+ (R = 0.4581, P = 0.0244) M2 monocytes, and the levels of plasma IL-10 (R = 0.4178, P = 0.0422) in this population of patients. There was no other significant correlation among these measures in this population. Collectively, increased numbers of CD14+CD163-and CD14+CD163-MAC387+ M1, and CD14+CD163+CD115+ M2 monocytes and elevated levels of plasma IL-10 may contribute to imbalance of pro-inflammatory and antiinflammatory responses during the process of MAP, and the numbers of CD14+CD163+CD115+ monocytes may serve as a biomarker for evaluating MAP severity.
DISCUSSION
Monocytes and macrophages are important in- [28] . In this study, the numbers of different subsets of peripheral blood monocytes and their potential association with disease severity were analyzed in 24 MAP patients. In comparison with healthy controls, significantly increased numbers of CD14+CD163-, CD14+CD163-MAC387+ and CD14+CD163-IL-12+ M1 monocytes and reduced numbers of CD14+CD163+IL-10+ monocytes were detected in the MAP patients. Furthermore, significantly higher levels of plasma IL-12 were observed in the MAP patients. More importantly, the levels of plasma CRP were positively correlated with the numbers of CD14+CD163-and CD14+CD163-MAC387+ M1 monocytes in the MAP patients. These data were consistent with a previous report of M1-polarized macrophages at the early stage in rats with AP [29] . Similarly, our previous study had found that peripheral blood polarized M1 monocytes are present in patients with tuberculous pleural effusion (TPE) [15] . Given that the levels of plasma CRP reflect the degrees of systemic inflammation, these findings support the notion that pro-inflammatory monocytes participate in the pathogenesis of MAP [30, 31] . Hence, targeting
pro-inflammatory M1 monocytes may be valuable for control of MAP. MAC387+ macrophages are recently recruiting macrophages, and increased numbers of MAC387+ macrophages are associated with poor prognosis in cancer patients [16] [17] [18] [32] [33] [34] . In this study, we found significantly increased numbers of circulating MAC387+ M1 monocytes in the MAP patients, similar to the findings in patients with encephalitis [16] . Furthermore, the numbers of CD14+CD163-MAC387+ M1 monocytes were positively associated with the levels of plasma CRP in the MAP patients. These data suggest that during the pathogenic process of MAP, continual differentiated M1 monocytes display in MAP patients, creating a positive feedback loop to strengthen proinflammatory responses. These novel findings may provide new insights into the pathogenesis of MAP.
During the pathogenic process of MAP, inflammatory stimuli damage the pancreatic acinar cells to release many inflammatory cytokines and mediators, which recruit leukocyte infiltrates, including M2 monocytes/ macrophages [28, 35] . M2 monocytes/macrophages can produce anti-inflammatory molecules that control inflammation and promote tissue repair [36] . In this study, we found significantly increased numbers of CD14+CD163+CD115+ M2 monocytes and significantly elevated levels of IL-10 in MAP patients. More importantly, the numbers of CD14+CD163+CD115+ M2 monocytes were positively correlated with the levels of plasma CRP and the APACHE II scores in MAP patients. Furthermore, the levels of plasma IL-10 were positively correlated with the APACHE II scores in the MAP patients. However, our previous study had shown a decreased number of peripheral blood CD14+CD163+CD115+ M2 monocytes, which is not significantly associated with the clinical measures in TPE patients [15] . We speculate the different results may stem from the different diseases. Engagement of CD115 by CSF-1 is crucial for the survival, differentiation and possible activation of monocytes/macrophages, and can polarize macrophages toward M2-type [21, 23] . Previous studies have shown that anti-CD115 can enhance anti-tumor immunity and ameliorate inflammation in humans and rodents [22, 23, [37] [38] [39] . The increased numbers of CD14+CD163+CD115+ M2 monocytes and elevated levels of plasma IL-10 may reflect a compensative response during the inflammatory process of MAP [40, 41] . Alternatively, CD14+CD163+CD115+ monocytes may through unknown factors promote the pathogenesis of MAP. Given that APACHE II scores and the levels of plasma CRP are two standard measures for the severity of inflammatory diseases, the positive correlations suggest that the numbers of CD14+CD163+CD115+ monocytes and the levels of plasma IL-10 may be valuable for evaluating the disease severity in patients with MAP.
IL-10 is a key anti-inflammatory cytokine and can control inflammation [42] . IL-10 is associated with immunosuppression in the late phase of severe AP [43] .
Previous studies have revealed elevated levels of plasma IL-10 and IL-12 in AP patients and that the levels of plasma IL-10 are biomarkers for evaluating the severity of AP [9, 10, 41, 44] . In this study, we also observed significantly higher concentrations of plasma IL-10 and IL-12 in MAP patients. The levels of plasma IL-10 were positively correlated with the APACHE II scores in the MAP patients. However, we found significantly reduced numbers of CD14+CD163+IL-10+ M2 monocytes in the MAP patients. The contradictory data suggest that the elevated levels of plasma IL-10 may stem from other anti-inflammatory cells, such as bone marrow derived mesenchymal stem cells (MSCs), regulatory T and B cells as well as some types of dendritic cells [45] . Indeed, infusion with human MSCs inhibits pancreatitis and ameliorates tissue damage by enhancing regulatory T cell responses in a rat model of MAP [46] and restoration of regulatory B cells inhibits pancreatitis in CD19-/-mice [47] . Accordingly, it is possible that the elevated levels of plasma IL-10 from other anti-inflammatory cells may compensatively limit inflammation during the pathogenic process of MAP. We are interested in further investigating the immunoregulation during the pathogenesis of MAP.
In conclusion, our data indicated significantly increased numbers of pro-inflammatory CD14+ CD163-, CD14+CD163-MAC387+ and CD14+CD163- IL-12+ M1 monocytes and reduced numbers of CD14+CD163+IL-10+ monocytes in the MAP patients. Furthermore, the levels of plasma CRP were positively correlated with the numbers of CD14+CD163-and CD14+CD163-MAC387+ M1 monocytes in the MAP patients. In addition, we detected significantly increased numbers of CD14+CD163+CD115+ monocytes and levels of plasma IL-10 in MAP patients. These data support the notion that pro-inflammatory monocytes participate in the pathogenesis of MAP. Moreover, the numbers of CD14+CD163+CD115+ monocytes were positively correlated with the levels of plasma CRP and the APACHE II scores in MAP patients, suggesting that the numbers of CD14+CD163+CD115+ monocytes may be a valuable biomarker for evaluating the severity of MAP. To the best of our knowledge, this was the first study on the numbers of peripheral blood different phenotypes of monocytes in patients with new-onset MAP. Our findings may provide new insights into the pathogenic process and immunoregulation of MAP. We recognized that our study had limitations, such as a relatively small sample size and the lack of longitudinally functional study of monocytes during the pathogenic process of MAP. We are interested in further investigating the values of these subsets of monocytes in a bigger population and in the moderate or severe acute pancreatitis to understand their roles in the pathogenesis of different types of AP.
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